May and June 2009 Conferences
-- May 27-29 BIOMARKER World Congress 2009
Philadelphia, PA
-- May 29-June 2 ASCO Annual Meeting (Booth #502)
Orlando, FL
-- June 2-3 CNS Clinical Trials
Brussels, Belgium
-- June 13-17 SNM 2009
Toronto, Ontario Canada
-- June 21-25 45th Annual DIA Meeting
(panel presentation on Clinical Data Management by
BioClinica VP Jonathan Andrus begins at 8:30 a.m. on June 25)
San Diego, CA
July 2009 Conferences
-- July 11 -16 ICAD 2009
Vienna, Austria
Jim Dorsey, Vice President of Marketing said, "This is an exciting time for BioClinica to demonstrate our superior service and consultative support for medical image data management and EDC. These capabilities were built upon a legacy of more than two decades of success as Bio-Imaging Technologies and Phoenix Data Systems. Participating in these global scientific and medical conferences helps us to communicate the unique benefits we offer and how we make clinical studies more manageable and cost effective for our clients."
About BioClinica
Bio-Imaging Technologies, Inc. d/b/a BioClinica is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. Created from the acquisition of Phoenix Data Systems, Inc. by Bio-Imaging Technologies, Inc., BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today's drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States and Europe, with business offices in the United States, France, Germany, United Kingdom and the Netherlands. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.
SOURCE: Bio-Imaging Technologies, Inc.
BioClinica Jim Dorsey, 267-757-3040 or Porter, LeVay & Rose, Inc. Linda Decker Bill Gordon 212-564-4700 or Diccicco Battista Communications Brian Gawron, 215-957-0300 Media Contact

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index